C. B. Rudolf

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

P. Neven, K. Zaman, R. Winterhalder, 2015, European journal of cancer.

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long‐Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)

R. Mirimanoff, R. Stupp, R. Stahel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort

E. Haralambieva, R. Grobholz, C. B. Rudolf, 2021, Annals of Hematology.

IMPACT OF EARLY PROPHYLACTIC CRANIAL IRRADIATION WITH HIPPOCAMPAL AVOIDANCE ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LIMITED DISEASE SMALL-CELL LUNG CANCER. A MULTICENTER PHASE II TRIAL (SAKK 15/12).

C. B. Rudolf, A. Allal, D. Aebersold, 2020, International journal of radiation oncology, biology, physics.

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

P. Neven, K. Zaman, R. Winterhalder, 2015, European journal of cancer.